We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.
- Recent ARVN Stock Price: $39.56
- Yearly Gain for ARVN stock: -47.99%
- Market Cap for ARVN stock: $2.17B
- P/E Ratio for ARVN stock: -8.55
Will ARVN's stock price go up? Is there an accurate ARVN stock forecast available?
TipRanks.com reports that Arvinas Holding Company currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ARVN forecast of n/a down to a low forecast of n/a. Arvinas Holding Company (ARVN)’s last closing stock price was $39.56 which would put the average price target at 96.16% upside.
In addition, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ARVN stock.
Other analysts covering ARVN include:
- Joon Lee of Truist Financial issued a Buy rating with the price target of $ 100 on 22 hours ago
- Peter Lawson of Barclays issued a Buy rating with the price target of $ 70 on 22 hours ago
- Li Watsek of Cantor Fitzgerald issued a Buy rating with the price target of $ 90 on 22 hours ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 81 on 1 day ago
If you are wondering if ARVN is a good stock to buy, here are 3rd party ratings for ARVN stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding Arvinas Holding Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARVN stock: Very Bullish
- Blogger Consensus for ARVN stock: n/a
- Media Buzz for ARVN stock: Medium
- Insider Signal for ARVN stock: n/a
- Investor Sentiment for ARVN stock: Neutral
- Hedge Fund signal for ARVN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ARVN stock including scouring the social networks like ARVN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARVN stock chart >>
Summary: Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.
- Recent CRBU Stock Price: $8.79
- Yearly Gain for CRBU stock: -50.23%
- Market Cap for CRBU stock: $534.37M
- P/E Ratio for CRBU stock: -5.843
Will CRBU's stock price go up? Is there an accurate CRBU stock forecast available?
TipRanks.com reports that Caribou Biosciences currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $27.17. The target pricing ranges from a high CRBU forecast of $37.00 down to a low forecast of $19.00. Caribou Biosciences (CRBU)’s last closing stock price was $8.79 which would put the average price target at 209.10% upside.
In addition, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on CRBU stock.
Other analysts covering CRBU include:
- Leah R. Cann of Brookline Capital Markets issued a Buy rating with the price target of $ 19 on 2 days ago
- Robert Burns of H.C. Wainwright issued a Buy rating with the price target of $ 27 on 2 days ago
- Geoff Meacham of Bank of America Securities issued a Buy rating with the price target of $ 27 on 1 week ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $ 19 on 2 weeks ago
If you are wondering if CRBU is a good stock to buy, here are 3rd party ratings for CRBU stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding Caribou Biosciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for CRBU stock: Very Bullish
- Blogger Consensus for CRBU stock: Bullish
- Media Buzz for CRBU stock: Low
- Insider Signal for CRBU stock: Neutral
- Investor Sentiment for CRBU stock: Neutral
- Hedge Fund signal for CRBU stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on CRBU stock including scouring the social networks like CRBU StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for CRBU stock chart >>
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
- Recent LLY Stock Price: $361.72
- Yearly Gain for LLY stock: 39.76%
- Market Cap for LLY stock: $342.90B
- P/E Ratio for LLY stock: 54.243
Will LLY's stock price go up? Is there an accurate LLY stock forecast available?
TipRanks.com reports that Eli Lilly & Co currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $382.71. The target pricing ranges from a high LLY forecast of $436.00 down to a low forecast of $313.00. Eli Lilly & Co (LLY)’s last closing stock price was $361.72 which would put the average price target at 5.80% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY stock.
Other analysts covering LLY include:
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $ 396 on 2 days ago
- Terence Flynn of Morgan Stanley issued a Buy rating with the price target of $ 436 on 6 days ago
- Trung Huynh of Credit Suisse issued a Buy rating with the price target of $ 395 on 6 days ago
If you are wondering if LLY is a good stock to buy, here are 3rd party ratings for LLY stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 21% (52 out of 251)
What is the sentiment on the street regarding Eli Lilly & Co? (Current ratings compiled by TipRanks.com)
- News Sentiment for LLY stock: Very Bullish
- Blogger Consensus for LLY stock: Bullish
- Media Buzz for LLY stock: Low
- Insider Signal for LLY stock: Negative
- Investor Sentiment for LLY stock: Very Positive
- Hedge Fund signal for LLY stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on LLY stock including scouring the social networks like LLY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LLY stock chart >>
Summary: Surgery Partners, Inc. is a healthcare services company. The Company's outpatient delivery model focused on providing solutions for surgical and related ancillary care in support of its patients and physicians. Its operating segment consists of Surgical Facility Services segment, Ancillary Services segment and Optical Services segment. Surgery Partners, Inc. is based in Nashville, Tennessee.
- Recent SGRY Stock Price: $27.49
- Yearly Gain for SGRY stock: -45.29%
- Market Cap for SGRY stock: $2.32B
- P/E Ratio for SGRY stock: -72.67
Will SGRY's stock price go up? Is there an accurate SGRY stock forecast available?
TipRanks.com reports that Surgery Partners currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $40.33. The target pricing ranges from a high SGRY forecast of $48.00 down to a low forecast of $35.00. Surgery Partners (SGRY)’s last closing stock price was $27.49 which would put the average price target at 46.71% upside.
In addition, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SGRY stock.
Other analysts covering SGRY include:
- Ben Hendrix of RBC Capital issued a Buy rating with the price target of $ 48 on 1 day ago
- Whit Mayo of SVB Securities issued a Buy rating with the price target of $ 40 on 2 days ago
- Tao Qiu of Stifel Nicolaus issued a Buy rating with the price target of $ 36 on 2 days ago
- Gary Taylor of Cowen & Co. issued a Hold rating with the price target of $ 35 on 1 week ago
If you are wondering if SGRY is a good stock to buy, here are 3rd party ratings for SGRY stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 39% (97 out of 251)
What is the sentiment on the street regarding Surgery Partners? (Current ratings compiled by TipRanks.com)
- News Sentiment for SGRY stock: Very Bullish
- Blogger Consensus for SGRY stock: Bullish
- Media Buzz for SGRY stock: Medium
- Insider Signal for SGRY stock: Neutral
- Investor Sentiment for SGRY stock: Very Negative
- Hedge Fund signal for SGRY stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on SGRY stock including scouring the social networks like SGRY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SGRY stock chart >>
Summary: Imago BioSciences Inc. is a clinical stage biopharmaceutical company. It involved in discovering new medicines for the treatment of myeloproliferative neoplasms. Imago BioSciences Inc. is based in SOUTH SAN FRANCISCO, Calif.
- Recent IMGO Stock Price: $35.64
- Yearly Gain for IMGO stock: 57.31%
- Market Cap for IMGO stock: $1.20B
- P/E Ratio for IMGO stock: -19.447
Will IMGO's stock price go up? Is there an accurate IMGO stock forecast available?
TipRanks.com reports that Imago BioSciences currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $36.00. The target pricing ranges from a high IMGO forecast of $36.00 down to a low forecast of $36.00. Imago BioSciences (IMGO)’s last closing stock price was $35.64 which would put the average price target at 1.01% upside.
In addition, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMGO stock.
Other analysts covering IMGO include:
- Marc Frahm of Cowen & Co. issued a Hold rating with the price target of $ 36 on 2 days ago
- Maury Raycroft of Jefferies issued a Hold rating with the price target of $ 36 on 2 days ago
- Robert Driscoll of Wedbush issued a Hold rating with the price target of $ 36 on 2 days ago
- Stephen Willey of Stifel Nicolaus issued a Buy rating with the price target of $ 35 on 6 months ago
If you are wondering if IMGO is a good stock to buy, here are 3rd party ratings for IMGO stock:
- TipRanks.com: Hold
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Top 24% (59 out of 251)
What is the sentiment on the street regarding Imago BioSciences? (Current ratings compiled by TipRanks.com)
- News Sentiment for IMGO stock: Very Bullish
- Blogger Consensus for IMGO stock: n/a
- Media Buzz for IMGO stock: Very High
- Insider Signal for IMGO stock: n/a
- Investor Sentiment for IMGO stock: n/a
- Hedge Fund signal for IMGO stock: Neutral
The stock market is extremely volatile, and you need to do your own research on IMGO stock including scouring the social networks like IMGO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IMGO stock chart >>
Summary: Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
- Recent ENTA Stock Price: $45
- Yearly Gain for ENTA stock: -46.36%
- Market Cap for ENTA stock: $941.74M
- P/E Ratio for ENTA stock: -7.919
Will ENTA's stock price go up? Is there an accurate ENTA stock forecast available?
TipRanks.com reports that Enanta Pharmaceuticals currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $75.40. The target pricing ranges from a high ENTA forecast of $96.00 down to a low forecast of $50.00. Enanta Pharmaceuticals (ENTA)’s last closing stock price was $45 which would put the average price target at 67.56% upside.
In addition, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ENTA stock.
Other analysts covering ENTA include:
- Roy Buchanan of JMP Securities issued a Buy rating with the price target of $ 96 on 1 day ago
- Brian Skorney of Robert W. Baird issued a Buy rating with the price target of $ 90 on 2 days ago
- Roanna Ruiz of SVB Securities issued a Hold rating with the price target of $ 50 on 2 days ago
- Yasmeen Rahimi of Piper Sandler issued a Buy rating with the price target of $ 87 on 1 month ago
If you are wondering if ENTA is a good stock to buy, here are 3rd party ratings for ENTA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 33% (83 out of 251)
What is the sentiment on the street regarding Enanta Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ENTA stock: Bearish
- Blogger Consensus for ENTA stock: Bullish
- Media Buzz for ENTA stock: Medium
- Insider Signal for ENTA stock: n/a
- Investor Sentiment for ENTA stock: n/a
- Hedge Fund signal for ENTA stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ENTA stock including scouring the social networks like ENTA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ENTA stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
